SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Open Access
- 7 August 2023
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (10) , 1725-1737
Abstract
Objective: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. Methods: DAY-BREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccina-tion) and postvaccination serum samples were included (n = 288). Spike recep-tor binding domain (RBD) antibody levels (seroconversion: =0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: =1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). Results: In fully vaccinated par-ticipants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 expo -sure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lym-phocyte count (ALC), age, body mass index, and sex did not. COVID-19- related AEs were reported in 10% (n = 15/148) of fully vaccinated participants -all were nonserious and not severe; all participants recovered. Interpretation: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.Keywords
Funding Information
- Bristol-Myers Squibb Canada
This publication has 32 references indexed in Scilit:
- Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 AntibodiesNeurology Neuroimmunology & Neuroinflammation, 2021
- Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapiesMultiple Sclerosis and Related Disorders, 2021
- SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayScience Advances, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesTherapeutic Advances in Neurological Disorders, 2021
- Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MSNeurology Neuroimmunology & Neuroinflammation, 2020
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialThe Lancet Neurology, 2019
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialThe Lancet Neurology, 2019
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2016
- Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activityBritish Journal of Pharmacology, 2016